ARTICLE
Clinical Study

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

Sung Hoon Sim1, In Hae Park1, Kyung Hae Jung2, Sung-Bae Kim3, Jin-Hee Ahn2, Kyung-Hun Lee3, Seock-Ah Im4, Young-Hyuck Im4, Yeon Hee Park4, Joohyuk Sohn5, Yu Jung Kim6, Suee Lee7, Hee-Jun Kim6, Yee Soo Chae9, Kyong Hwa Park10, Byung-Ho Nam11, Keun Seok Lee1 and Jungsil Ro1

BACKGROUND: The continuum of anti-HER2 agents is a standard treatment of HER2+ metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments.

METHODS: A total of 149 patients were randomly assigned to lapatinib with vinorelbine (LV) (n = 75; lapatinib, 1000 mg daily; vinorelbine 20 mg/m² D1, D8 q3w) or vinorelbine (V) (n = 74; 30 mg/m² D1, D8 q3w). The primary endpoint was progression-free survival (PFS) rate at 18 weeks.

RESULTS: The median number of previous anti-HER2 therapies was 2 (range 2–5). There was no significant difference in PFS rate at 18 weeks between LV and V arms (45.9% vs 38.9%, p = 0.40). ORR was 19.7% in LV arm, and 16.9% in V arm (p = 0.88). PFS and OS did not differ between two arms (LV vs V; median PFS, 16 vs 12 weeks, HR = 0.86, 95% CI 0.61–1.22; median OS, 15.0 vs 18.9 months, HR = 1.07, 95% CI 0.72–1.58). Toxicity profiles were similar in both arms and all were manageable.

CONCLUSIONS: Lapatinib plus vinorelbine treatment was tolerable; however, it failed to demonstrate the clinical benefits over vinorelbine alone in patients with HER2+ MBC after progression on both trastuzumab and lapatinib.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number NCT01730677.

British Journal of Cancer (2019) 121:985–990; https://doi.org/10.1038/s41416-019-0618-z

BACKGROUND
Recent advances in human epidermal growth factor receptor 2 (HER2) therapy have led to new paths of treatment in HER2-positive advanced breast cancer. Since the first anti-HER2 monoclonal antibody, trastuzumab, was introduced into the treatment of HER2-positive breast cancer, new anti-HER2 agents have been developed and incorporated into the armamentarium over two decades. As a result, the median overall survival (OS) of metastatic HER2-positive breast cancer patients has reached over two decades.1 Despite effective new agents, metastatic breast cancer remains incurable since the tumours eventually acquire resistance to the agents. Therefore, it is still necessary and challenging to develop subsequent treatment strategies.

Previous clinical trials of the combination of lapatinib or trastuzumab after trastuzumab failure yielded better survival than treatment with chemotherapy alone.2–4 Therefore, maintaining anti-HER2 treatment has been strongly recommended and becomes the mainstay,5 even after treatments in combination with anti-HER2 therapy show failure.

Lapatinib is a small molecule that inhibits epidermal growth factor receptor/HER2 signalling in cancer cells, and its treatment efficacy has been well explored in breast cancer.2–4,6 However, the efficacy of continuing lapatinib after the failure of both trastuzumab and lapatinib has not been evaluated. This study aimed to evaluate the efficacy of adding lapatinib to vinorelbine in patients who experienced disease progression after lapatinib and trastuzumab treatment.

PATIENTS AND METHODS
Study design and patients
This open-label, multicentre, randomised phase 2 study was conducted by Korean Cancer Study Group (KCSG, KCSG BR11-16) in South Korea. Patients with metastatic HER2-positive breast...
Study treatment and assessment

In the LV arm, patients received oral lapatinib, 1000 mg daily, and intravenous infusions of vinorelbine at a dose of 20 mg/m² on days 1 and 8, every 3 weeks. The dose of combination treatment was determined based on previous data and modified for safety concerns.\(^8\) In the V arm, patients received 30 mg/m² of vinorelbine on days 1 and 8, every 3 weeks. Tumors were assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 at screening and every 6 weeks from the initiation of treatment. Adverse events were evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at the baseline and throughout treatment.

Statistical analysis

Sample size was considered based on the progression-free (survival) rate as a binary outcome at 18 weeks from treatment initiation as a primary endpoint. This primary endpoint was chosen to avoid possible biases in determining progression times in a non-blinded randomised trial like our study.\(^9\) We set the median progression-free survival to be 2.5 months for vinorelbine arm, and 4 months for lapatinib and vinorelbine combination arm based on previous studies.\(^10,11\) In this condition, the PFS rate at 18 weeks would be 31.6% for control arm, and 48.7% for combination arm. With 80% power and one-sided type I error rate of 0.1, a total of 142 patients were required. Considering 5% dropout, the trial would need to recruit ~150 patients.

All randomised patients were included in the intention-to-treat (ITT) population, which was used for all survival analyses. The progression-free survival rates at 18 weeks were estimated based on Kaplan–Meier method, and the differences between two groups were compared by using Greenwood’s variance estimator. Safety was accessed in the safety population that had received at least one dose of study treatment. The ORR was evaluated amongst patients who had measurable disease and calculated as the proportion of patients with complete or partial tumour response. PFS and OS were estimated by the Kaplan–Meier method, and compared by using the log-rank test. Cox proportional hazards analysis was used to assess the experimental treatment effect against the control with variables expected to affect treatment response.

RESULTS

Baseline characteristics and study treatment

Between December 2011 and March 2018, 166 patients were enrolled and followed up. Eleven patients showed screening failure, and six patients withdrew consent before randomisation. Therefore, 149 patients were randomised to the lapatinib plus vinorelbine arm (n = 75) and to the vinorelbine arm (n = 74) (Fig. 1). Two patients in the vinorelbine arm withdrew their consent after randomisation. Thus, 147 patients received at least
one dose of the assigned treatment. There was no statistical
difference in the baseline characteristics between the two groups
(Table 1). The hormone receptor positivity rate was 53.4%
amongst patients in the lapatinib plus vinorelbine arm and
45.9% in the vinorelbine arm.

The number of previous anti-HER2 treatment regimens was 2
(range, 2–5). Seventy-four patients (49.6%) had CR or PR from prior
lapatinib treatment, and 69.1% of patients had received the last
dose of lapatinib within 6 months prior to randomisation.

Efficacy

The 18-week PFS rate was 45.9% in the LV arm, and 38.9% in the V
arm. The difference was 7.02% (95% CI, −9.4 to 23.43%), which
was not significantly different (P = 0.402, Table 2). One hundred
and twenty patients had measurable disease on the baseline
images, which were evaluated for response analysis. Objective
responses (CR + PR) were observed in 12 (19.7%) patients in LV
arm (n = 61) and 10 (16.9%) in the V arm (n = 59), which showed
no statistical difference (P = 0.881, Table 3). The median PFS was
16.0 weeks (95% confidence interval [CI] 12.0–21.0) in the LV arm
and 12.0 weeks (95% CI 11.0–18.4) in the V arm (P = 0.414, Fig. 2a)
without statistical difference. Likewise, the median OS was similar
between the two arms (15.0 months, 95% CI 11.5–23.3 in the LV
arm vs 18.9 months, 95% CI 13.3–29.1 in the V arm; P = 0.716,
Fig. 2b). In the subgroup analysis for progression at 18 weeks,
hormone receptor negativity, prior responsiveness to lapatinib (CR
or PR) and the last dose of lapatinib within 6 months tended to
favour LV combination treatment with no statistical significance

| Table 1. Patient characteristics |
|---------------------------------|
| Age, median | Median 53 (28–80) | 54 (28–80) | 52 (30–74) | 0.349 |
| ECOG PS* | 0 | 38 (25.5%) | 19 | 19 | 0.943 |
| 1 | 108 (72.5%) | 55 | 53 |
| 2 | 3 (2.0%) | 1 | 2 |
| Menopausal status | Postmenopausal | 117 (78.5%) | 57 | 60 | 0.567 |
| Premenopausal | 30 (20.1%) | 17 | 13 |
| Not applicable (hysterectomy) | 2 (1.4%) | 1 | 1 |
| De novo stage IV vs recurrence | De novo stage IV | 51 (34.2%) | 27 | 24 | 0.774 |
| Recurrence | 98 (65.8%) | 48 | 50 |
| Histology | IDC | 147 (98.6%) | 74 | 73 | 0.999 |
| ILC | 1 (0.7%) | 1 |
| Others | 1 (0.7%) | 0 | 1 |
| ER/PgR | Positive | 73 (49.0%) | 39 (53.4) | 34 (45.9) | 0.565 |
| Negative | 76 (51.0%) | 36 | 40 |
| Visceral metastasis | Yes | 75 (50.3%) | 38 | 37 | 0.999 |
| No | 74 (49.7%) | 37 | 37 |
| Number of previous chemotherapy | 1 | 18 (12.1%) | 9 | 9 | 0.252 |
| 2 | 59 (39.6%) | 25 | 34 |
| ≥3 | 72 (48.3%) | 41 | 31 |
| Previous lines of anti-HER2 treatment | 2 | 121 (81.2%) | 65 | 56 | 0.131 |
| ≥3 | 28 (18.8%) | 10 | 18 |
| Previous response to lapatinib | CR + PR | 74 (49.6%) | 38 | 36 | 0.934 |
| SD ≥ 12 weeks | 75 (50.4%) | 37 | 38 |
| Last lapatinib use | Within 6 months | 103 (69.1) | 52 | 51 | 0.999 |
| Before 6 months | 46 (30.9) | 23 | 23 |

ECOG PS: Eastern Cooperative Oncology Group performance status, IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, CR: complete response, PR: partial response, SD: stable disease

| Table 2. Progression-free survival rate at 18 weeks after treatment |
|-----------------------|
| LV, n = 75 | V, n = 74 |
| 18-week progression events, no. (%) | 69 (92) | 65 (87.8) |
| 18-week PFS | 45.9% | 38.9% |

| Table 3. Response rate according to treatment arms |
|---------------------------------|
| Objective response rate (ORR) (n = 120) |
| LV arm | V arm |
| CR or PR | 12 | 10 |
| SD/PD | 49 | 49 |
| ORR | 19.67% | 16.94% |
| FAS (n = 147) | 19.67% | 16.94% |
| CBR | 25 (33.3%) | 17 (23.6%) |
| CR + PR + SD ≥ 24 weeks | 50 (66.7%) | 55 (76.4%) |

FAS: full analysis set, CBR: clinical benefit ratio, CR: complete response, PR: partial response, SD: stable disease
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in…

SH Sim et al.

Fig. 2 Survival analysis in the intention-to-treat (ITT) population. Kaplan–Meier curve for progression-free survival (PFS) (a) and overall survival (OS) (b) between lapatinib with vinorelbine (LV) and vinorelbine alone (V)

In the subgroup analyses of PFS and OS, there was no difference between the two arms according to prior responsiveness to lapatinib and last lapatinib use (Supplementary Figs.).

Toxicities
The toxicities of both study drugs were mild and manageable, except for neutropenia. In the safety population, grade 3 or 4 neutropenia occurred at a rate of 44% in the LV arm and 65.2% in the V arm. The incidence of febrile neutropenia was low (6% in the LV arm and 8% in the V arm). No grade 3 or 4 skin toxicity or hand–foot syndrome was observed in the LV arm. Both arms showed comparable frequencies of the other forms of toxicity (Supplementary Table 1).

DISCUSSION
In this trial, we investigated the clinical benefit of adding lapatinib to vinorelbine in patients who experienced disease progression on both trastuzumab and lapatinib treatment. The combination treatment of lapatinib and vinorelbine was tolerable. However, clinical outcomes of the combination treatment were not different from those of vinorelbine alone.

After the failure of first-line anti-HER2 treatment, the continuum of anti-HER2 agents has become the mainstay of treatment. Currently, T-DM1 is recommended as the second-line therapy after trastuzumab plus pertuzumab-containing therapy. After that, trastuzumab plus other chemotherapeutic agents or lapatinib plus capecitabine is considered. At the time of beginning this study, T-DM1 or pertuzumab was not available yet at the routine practice in Korea. Therefore, the majority of patients in this study had been exposed only to trastuzumab and lapatinib before entering in this study.

Various resistance mechanisms of anti-HER2 therapy have been suggested, including upregulation of ligands, increased signalling from other HER family receptors and loss of phosphatase and tensin homologue (PTEN) with activation of the PI3K pathway.13–15 These mechanisms suggest that persistent HER2 signal activation can be one of the major drivers of tumour proliferation after trastuzumab failure. Recent report showed that ER signal is one of the HER2-resistance signal pathways, and blocking both ER and HER2 signal with fulvestrant and neratinib could be a good way to overcome HER2 resistance. In this study, ~50% of patients had ER+/HER2+ breast cancer. However, unfortunately we could not evaluate the efficacy of prior endocrine treatment, which was not planned from the beginning.

In clinical trials pertaining to anti-HER2 treatment, lapatinib with capecitabine after trastuzumab failure exhibited longer PFS compared with capecitabine alone (combination therapy, 8.4 months vs monotherapy, 4.4 months). Combined lapatinib with trastuzumab treatment demonstrated prolonged survival compared with lapatinib as monotherapy. Later, trastuzumab in combination with capecitabine also showed better survival outcomes than capecitabine alone after trastuzumab failure.

In the current trial, however, continuing lapatinib after progression while on two prior anti-HER2 agents failed to improve the PFS rate. According to our results, the reuse of lapatinib or continuing lapatinib after progression while on lapatinib did not seem to be clinically effective. This may be explained by the different mechanisms underlying trastuzumab resistance, which is associated with incomplete blockade of the HER2-related pathway. In contrast, lapatinib resistance could be related to the induction of other proliferation pathways such as hormone receptor signals. In our subgroup analysis, the hormone receptor-negative patients showed a tendency towards favourable outcome on lapatinib treatment compared with the hormone receptor-positive group. Such a different resistance mechanism may have affected the efficacy of lapatinib reuse.

On the other hand, HER2 receptors could be modified with the use of lapatinib and may affect the result, as suggested by some in vitro data where inactive HER2 receptors accumulated on tumour cells after lapatinib treatment. Although the accumulation is not linked directly to the resistance, it suggests that reuse of trastuzumab is a better alternative when the tumour has acquired resistance to lapatinib. This is also supported by a small outcome report. After progression on lapatinib treatment, retreatment with trastuzumab showed a 47% clinical benefit.

Nowadays, the new generation of HER2-targeting tyrosine kinase inhibitors such as poziotinib and neratinib are also gaining attention. Poziotinib showed meaningful activity in heavily treated HER2-positive breast cancer cases and neratinib could be effective as third-line treatment compared with lapatinib (NALA trial, http://www.pumabiotechnology.com/pr20181217.html). They
Conversion of lapatinib from single-agent (SA) treatment to combination (C) treatment is a feasible strategy for patients with metastatic HER2-positive breast cancer. We conducted a prospective, single-arm, open-label, randomized phase 2 study comparing lapatinib and vinorelbine vs. vinorelbine alone in patients with lapatinib refractory metastatic HER2-positive breast cancer. Of 82 patients initially enrolled, 66 were included in the primary analysis. The median PFS was 5.3 months (95% CI: 4.3 – 6.2) in the SA arm and 4.3 months (95% CI: 2.7 – 6.2) in the C arm (p = 0.15) (Table 1). The C arm trended towards a better response rate (RR) (p = 0.01) and higher overall response rate (ORR) compared to the SA arm. We conclude that conversion of SA to C treatment is a feasible strategy for patients with lapatinib refractory metastatic HER2-positive breast cancer. There is a need to develop novel strategies for patients failing both SA and C treatments.

**Funding:** This study was supported by GSK (1240970-1) and Research Grand from National Cancer Center Korea (1210530).

**Consent to publish:** All informed consents were obtained. This report does not contain any individual person’s information.

**Data availability:** Data supporting the results will be provided on public websites or archives.

**Note:** This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**ACKNOWLEDGEMENTS**
We thank the patients and their families, as well as all the investigators and study team.

**AUTHOR CONTRIBUTIONS**
Conception and design: I.H.P. and J.R. Provision of study material or patients: K.H.J., S.B.K., J.H.A., K.H.L., S.A.I., Y.H.I., Y.H.P., J.S., Y.J.K., S.L., H.J.K., Y.S.C., K.H.P., B.H.N. and K.S.L. Collection and assembly of the data: K.H.J., S.B.K., J.H.A., K.H.L., S.A.I., Y.H.I., Y.H.P., J.S., Y.J.K., S.L., H.J.K., Y.S.C., K.H.P., B.H.N. and K.S.L. Data analysis and interpretation: S.H.S., I.H.P. and J.R. Paper writing: S.H.S. Final approval of the paper: all authors.

**ADDITIONAL INFORMATION**
Supplementary information is available for this paper at https://doi.org/10.1038/s41416-019-0618-z.

**Competing interests:** The authors declare no competing interests.

**Ethics approval and consent to participate:** The study protocol and its amendments were approved by the institutional review board of each site (supplementary document). This study was conducted in accordance with the tenets of the Declaration of Helsinki and the provisions of the Good Clinical Practice guidelines (ClinicalTrials.gov number NCT01730677).

**REFERENCES**
1. Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
2. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
3. von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J. Clin. Oncol. 27, 1999–2006 (2009).
4. Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124–1130 (2010).
5. Network NCC. Breast cancer (version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 22, 2019.
6. Takano, T., Tsurutani, J., Takahashi, M., Yamanaka, T., Sakai, K., Ito, Y. et al. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast 40, 67–75 (2018).
7. Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H. et al. Recommendations for human epidermal growth factor receptor 2 testing in
in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997–4013 (2013).
8. Rezai, K., Urien, S., Isambert, N., Roche, H., Dieras, V., Berille, J. et al. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother. Pharmacol. 68, 1529–1536 (2011).
9. Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P. & Smith, M. A. Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol. 23, 7199–7206 (2005).
10. Park, I. H., Lee, K. S. & Ro, J. Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin. Breast Cancer 15, e55–62 (2015).
11. Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M. et al. Trastuzumab emtansine versus treatment of physician’s choice for pre-treated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 689–699 (2014).
12. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
13. Spector, N. L. & Blackwell, K. L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27, 5838–5847 (2009).
14. Tolaney, S. M. & Krop, I. E. Mechanisms of trastuzumab resistance in breast cancer. Anti-cancer Agents Med. Chem. 9, 348–355 (2009).
15. Nahta, R. & Esteve, F. J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8, 215 (2006).
16. Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S. et al. Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2(+) breast cancers: implications to the ExteNET trial. Clin. Cancer Res. 25, 771–783 (2019).
17. Wang, Y. C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X. et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13, R121 (2011).
18. Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A. et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clinical Cancer Res. 13, 4909–4919 (2007).
19. Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P. et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878–5887 (2008).
20. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803–814 (2009).
21. Gori, S., Montemurro, F., Spazzapan, S., Metro, G., Foglietta, J., Bisagni, G. et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann. Oncol. 23, 1436–1441 (2012).
22. Park, Y. H., Lee, K. H., Sohn, J. H., Lee, K. S., Jung, K. H., Kim, J. H. et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int. J. Cancer 143, 3240–3247 (2018).
23. Pernas, S. & Tolaney, S. M. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 11, 1758835919833519 (2019).